Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Case Comprehensive Cancer Center
With
National Cancer Institute (NCI)
OBJECTIVES:
* Determine the change in peripheral nerve function in cancer patients during and after treatment with chemotherapy or biologic therapy.
* Determine the clinical measurement of hearing-related air and bone conduction and vibratory sensation in these patients.
* Correlate the changes in orthostatic blood pressure using both the Vasotrac automated blood pressure device and the standard clinical automated blood pressure equipment.
* Determine the patient's perception of hearing quality before and after treatment with chemotherapy or biologic therapy.
OUTLINE: This is a multicenter study.
Patients undergo a 1-hour peripheral nerve function assessment, including hearing, vibratory sensation, and blood pressure testing, at baseline and then at 4, 8, and 12 weeks during treatment with chemotherapy or biologic therapy.
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.
Age
21–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Histologically confirmed diagnosis of cancer
Scheduled to be treated with 1 of the following agents:
* Cisplatin/paclitaxel combination
* Biologic therapy with high-dose interferon alfa
PATIENT CHARACTERISTICS:
Normal vision OR vision corrected with glasses or contact lenses
No diseases or disorders reducing peripheral nerve function, including any of the following:
* Diabetes mellitus
* HIV/AIDS
* Uremia
* Spinal injuries
* Alcoholism
* CNS problems
No hearing impairment
PRIOR CONCURRENT THERAPY:
No prior biologic therapy or neurotoxic chemotherapy